ventricular arrhythmias and sudden cardiac death
in review
7 min read
Updated 2026-10-30
ventricular arrhythmias and sudden cardiac death
Unstable → shock. Stable monomorphic VT with structural heart disease → DCCV or procainamide. Polymorphic VT → check the QT: normal QT = ischaemia until proven otherwise (cath lab); long QT = torsades → magnesium, K⁺ ≥4, raise the heart rate, stop QT drugs. Wide-complex tachycardia of uncertain origin is VT. Long term: beta-blocker for all, ICD if VT/VF has no reversible cause, sotalol/amiodarone or ablation to suppress recurrences. AADs other than beta-blockers do not improve survival.
sustained VT / electrical storm — admission bundle
- pulseless or unstable: defibrillate or synchronised DCCV, ACLS
- shock-refractory VF/pVT: amiodarone 300 mg IV (then 150 mg) or lidocaine 100 mg IV (then 50 mg)
- stable monomorphic VT: DCCV or procainamide 10 mg/kg over 20 min → 1–2 mg/min
- stable VT second line: amiodarone 150 mg over 10 min → 1 mg/min × 6 h → 0.5 mg/min × 18 h, or lidocaine 1 mg/kg → 1–2 mg/min
- polymorphic VT with normal QT or STEMI: urgent angiography; IV beta-blocker, amiodarone or lidocaine
- torsades: IV magnesium, K⁺ ≥4.0, stop QT-prolonging drugs; overdrive pacing if bradycardic
- no CCBs for wide-complex tachycardia of unknown origin
- electrical storm (≥3 episodes in 24 h): non-selective beta-blocker (propranolol 40 mg PO q6h if BP allows) + IV amiodarone
- electrical storm: sedation, early EP involvement, ablation; amiodarone load 1–2 g over 24 h
- K⁺ ≥4.0, Mg²⁺ ≥0.9–1.0 mmol/L
- 12-lead ECG, telemetry, electrolytes, troponin, TTE; interrogate ICD and review programming
- cause unclear after echo and angiography: CMR
- treat HF and ischaemia
- VF/VT without reversible cause: secondary-prevention ICD → ventricular arrhythmias and sudden cardiac death
torsades de pointes
Polymorphic VT with a long QT in sinus beats. Pulseless or unstable → defibrillate.
first
- magnesium 2 g IV — works even with a normal serum Mg²⁺
- stop QT-prolonging drugs; K⁺ to ≥4.0
then / if needed
- recurrent with bradycardia or pauses → raise the rate: overdrive pacing or isoproterenol
avoid
- amiodarone — prolongs the QT further
mechanism → management
- Monomorphic VT = re-entry around fixed scar (prior MI, cardiomyopathy) → recurs predictably → ablation targets the circuit; ICD for death prevention
- Polymorphic VT with normal QT = acute ischaemia or channelopathy → revascularise; beta-blocker
- Torsades = early afterdepolarisations from prolonged repolarisation, worse at slow rates and after pauses → magnesium (suppresses EADs even with normal serum Mg), K⁺ repletion, increase HR (pacing) and remove the QT drug
- Sympathetic drive sustains storm → beta-blockade (non-selective, e.g. propranolol), sedation
- Wide-complex tachycardia + verapamil/diltiazem → vasodilation and negative inotropy in VT → collapse. Presume VT
- AADs suppress but don’t save lives in structural heart disease → the ICD prevents death; drugs and ablation reduce shocks
acute management
graph TD
A[Sustained VT/VF] --> B{Pulse and stable?}
B -->|no| C[Defibrillate / synchronised DCCV + ACLS<br/>shock-refractory → IV amiodarone or lidocaine]
B -->|yes| D{Morphology}
D -->|monomorphic| E[DCCV or IV procainamide<br/>amiodarone or lidocaine second line]
D -->|polymorphic| F{QT in sinus beats}
F -->|normal| G[Ischaemia → urgent angiography<br/>IV beta-blocker, amiodarone or lidocaine]
F -->|prolonged: torsades| H[IV magnesium, K⁺ ≥4.0<br/>stop QT drugs, overdrive pacing<br/>non-selective beta-blocker]
C --> I{≥3 episodes in 24 h?}
I -->|electrical storm| J[Non-selective beta-blocker + IV amiodarone<br/>sedation, early EP involvement, ablation]
| Drug | Dose | Notes |
|---|---|---|
| amiodarone (arrest) | 300 mg IV push (150 mg if <45 kg), then 150 mg | after failed shock; not if torsades suspected (CCS) |
| lidocaine (arrest) | 100 mg IV push (50 mg if <45 kg), then 50 mg | alternative to amiodarone |
| procainamide (stable VT) | 10 mg/kg over 20 min → 1–2 mg/min; slow if hypotensive | first-line drug for stable monomorphic VT (CCS strong); fewer adverse events than amiodarone in PROCAMIO (2016) |
| amiodarone (stable VT / storm) | 150 mg over 10 min → 1 mg/min × 6 h → 0.5 mg/min × 18 h; storm target 1–2 g over 24 h | second-line for stable VT |
| lidocaine (stable VT) | 1 mg/kg IV → 1–2 mg/min | second-line; ischaemic VT |
| propranolol (storm) | 40 mg PO q6h if BP stable | non-selective preferred; esmolol to test tolerance |
- Polymorphic VT/VF with STEMI → emergency angiography and revascularisation
- Electrical storm (≥3 episodes in 24 h): beta-blocker + IV amiodarone (strong), sedation/anaesthesia, treat HF and ischaemia, K⁺ ≥4.0 and Mg²⁺ ≥0.9–1.0 mmol/L, check ICD programming → ablation
- Torsades refractory to Mg with bradycardia → temporary pacing to raise the rate
- Digoxin toxicity with VA → digoxin-specific antibody fragments
- Not useful/harmful: CCBs in wide-complex tachycardia of unknown origin; magnesium in VF not due to torsades; prophylactic lidocaine or amiodarone in AMI; high-dose adrenaline
- Initial workup: ECG, electrolytes, troponin, echo, ICD interrogation; CMR if the cause isn’t clear (strong)
- Post-arrest care, TTM, comatose post-arrest angiography → post-cardiac arrest care
long-term management
secondary prevention ICD
| Situation | ICD | Strength (CCS 2016) |
|---|---|---|
| cardiac arrest from VT/VF, no reversible cause | yes | strong |
| sustained VT with significant structural heart disease, no reversible cause | yes | strong |
| sustained VT/VF >48 h after MI or revascularisation | consider | weak |
| unexplained syncope + structural heart disease + inducible VT at EPS | yes | strong |
| syncope + structural heart disease, VT/VF the likely cause, high recurrence risk | consider | weak |
- ICD over antiarrhythmics: ↓ mortality vs (mostly) amiodarone in AVID (1997)
- Only if meaningful survival >1 year expected; no ICD when comorbidities make survival gain unlikely
- VT/VF within 48 h of an acute MI = reversible → revascularise, no ICD on that basis
- Revascularisation alone does not prevent recurrent monomorphic VT; no ICD in incessant VT/VF until the arrhythmia is controlled (both III, AHA)
- Primary prevention ICD criteria (LVEF thresholds) → HFrEF management
- Waiting period for ICD (e.g. ≤40 days post-MI, new cardiomyopathy) or explanted ICD → wearable defibrillator may be considered
- Driving restrictions → fitness to drive (cardiac)
suppression of recurrent VT
- Beta-blocker at maximally tolerated dose in all with structural heart disease (strong)
- Sotalol or amiodarone first-line AAD (strong) — amiodarone more effective, more toxic. Doses → antiarrhythmics
- Catheter ablation:
- ischaemic cardiomyopathy, monomorphic VT despite sotalol/amiodarone → ablation (strong). Ablation beat AAD escalation for death, storm or appropriate shock in VANISH (2016)
- ischaemic, first-line alongside beta-blocker → consider (conditional)
- non-ischaemic cardiomyopathy → second line after AAD failure (lower success, often epicardial)
- Refractory: mexiletine + amiodarone, dofetilide; then specialised ablation, stereotactic radiotherapy, cardiac sympathetic denervation
- Optimise ICD programming (long detection, ATP) to cut shocks
- Screen for psychological distress after shocks (strong)
frequent PVCs
- PVC burden generally >15% with falling LVEF → suspect PVC-induced cardiomyopathy → ablation or beta-blocker/amiodarone; LVEF often recovers
inherited arrhythmia syndromes
| Syndrome | Clue | Treatment | ICD |
|---|---|---|---|
| long QT | prolonged QTc (≥480 ms supports diagnosis), syncope or arrest; high risk if QTc >500, LQT2/LQT3, symptom onset <10 y | beta-blocker if QTc >470 (strong), reasonable if <470; avoid QT-prolonging drugs; correct K⁺/Mg²⁺; mexiletine or cardiac sympathetic denervation if breakthrough | after arrest; recurrent events despite beta-blocker |
| Brugada | coved ST elevation in V1–V2 (type 1), spontaneous or provoked by procainamide/flecainide challenge | avoid Na⁺-channel blockers; quinidine or epicardial ablation for recurrent shocks | spontaneous type 1 + arrest, sustained VA or arrhythmic syncope. Drug-induced pattern only, asymptomatic → observe |
| CPVT | exertional bidirectional or polymorphic VT, structurally normal heart | beta-blocker (strong); add flecainide or sympathetic denervation if breakthrough | recurrent VT/syncope despite therapy |
| short QT | short QTc, AF, family SCD | quinidine; isoproterenol for storm | after arrest |
- Genetic counselling and testing in the proband; screen first-degree relatives (strong)
- Unexplained SCD → postmortem including genetic testing; cardiology screening of the family
- HCM, ARVC, sarcoid, myocarditis, LVAD and neuromuscular disease have disease-specific ICD criteria → hypertrophic cardiomyopathy, dilated cardiomyopathy
Prepared 2026-10-30. Not yet verified — check every number against the sources.